| |
|
|
| |
Closed Drug Transfer for Oncology
Therapeutics
Devices, Therapeutic
Markets and Prospects
|
Publication: June 2010
Product Code: CDT610E
|
The administration of drugs deemed hazardous to humans has
been receiving increasing amounts of scrutiny in recent
years as the dangers of these substances become more clearly
understood. For caregivers and their patients, the
therapeutic area that is at the forefront of attempts to
mitigate exposure to cytotoxic drugs is clinical oncology, a
field that – in spite of promising new drugs based on
therapeutic antibodies – continues to rely heavily on
antineoplastics, a class that includes alkylating agents and
antimetabolites, to treat a wide range of cancers.
Regulatory and industry efforts to create standards and
procedures designed to protect workers and patients from
accidental and incidental exposure to cytotoxics are being
driven by data that suggests a causal link between exposure
and health issues. Studies of nurses who work with cytotoxic
drugs on a regular basis have found a statistically higher
rate of spontaneous abortion. Several companies are
responding to this unmet need by commercializing devices for
closed transfer of these drugs. As the market evolves and
user acceptance increases, so too will the impact of these
products on oncology therapy protocols and drug delivery |
|
Highlights |
· Analyzes the impact of
drug toxicity and safety factors on therapeutic oncology
market segments, market dynamics and market demographics
· Provides detailed
analysis of closed drug transfer products for the
handing of cytotoxic drugs
· Analyzes demand drivers
and competitive factors influencing closed drug transfer
adoption
· Charts product data and
provides forecasts to 2013
· Profiles closed drug
transfer device participants, their
product development activities, business
strategies, and corporate alliances and
affiliations
|
|
Summary of Contents |
Executive Summary
Oncology Therapeutics
Market Dynamics
Therapeutic Trends and Issues
The Administration of injectable/Infusable
Antineoplastics
Drug Packaging and Administration
Technology
Closed Drug Transfer Market Drivers
Competitive Landscape
Risk Factors
Closed
Drug Transfer Design Factors
Key System
Design Elements
Human Engineering/Ergonomics
Material Selection Issues
Drug Reconstitution and
Dilution
Oncology Therapeutics Medication Safety
Oncology Drug Administration and Dosing
Drug-Specific Dosing Modification and Individualized
Dosing
Closed Drug Transfer – Commercial
Devices
Codan Cyto (Codan)
Cyto-Set (B.Braun)
EquaShield (PlastMed)
OnGuard/Tevadaptor (B.
Braun/Teva)
PhaSeal (Carmel Pharma)
SecurMix (Eurospital)
Spiros (ICU Medical)
SureConnect (Baxa)
Texium
(CareFusion)
Market Factors
Regulatory
Issues
Caregiver Compliance
Level of
Complexity and Ease of Use
Healthcare Economics
Business Models and Strategies
Market
Assessments and Forecasts
North America
Europe
Asia
Other Geographic Markets
Closed Drug Transfer – Market Participant Profiles
|
|
|
|
|
